Heron Therapeutics Announces Third Quarter 2026 Financial Results

Heron posts another loss, revenue declines, and plans to sell nearly all assets to CorMedix.

What the company is saying

Heron Therapeutics reports Q3 2026 net revenue of $35.3 million, down from $38.2 million a year earlier and $37.7 million in the previous quarter. The company highlights Acute Care franchise growth—up 22.5% year-over-year for the quarter and 32.4% for the nine months—driven by ZYNRELEF ($10.6 million Q3, $31.9 million YTD) and APONVIE ($4.5 million Q3, $12.2 million YTD). Oncology Supportive Care revenue fell to $20.1 million in Q3, with CINVANTI contributing $20.0 million and SUSTOL sales ceasing entirely as of September 30, 2026. Heron emphasizes a definitive asset purchase agreement with CorMedix Therapeutics for the sale of substantially all assets, pending stockholder approval and standard closing conditions. The company withdrew full-year 2026 financial guidance in August and is not providing new guidance. The tone is factual, with no attempt to obscure the operational or financial challenges.

What the data suggests

Heron's Q3 2026 financials show total net revenue of $35.3 million, a 7.8% decline from $38.2 million in Q3 2025 and a sequential drop from $37.7 million in Q2 2026. The company ended the quarter with $23.4 million in cash, cash equivalents, and short-term investments. Acute Care franchise revenue rose to $15.1 million in Q3, up 22.5% year-over-year, but Oncology revenue dropped 22.2% to $20.1 million. ZYNRELEF and APONVIE posted year-over-year growth, while CINVANTI and SUSTOL declined sharply, with SUSTOL sales ending completely. Cost of product sales was $8.96 million in Q3, gross profit was $26.3 million, and operating expenses totaled $28.0 million. Heron reported a Q3 operating loss of $1.7 million and a net loss of $5.0 million, with a nine-month net loss of $18.6 million. The company is not profitable and continues to burn cash. The pending asset sale to CorMedix is not yet complete and is contingent on shareholder approval and other conditions. Withdrawal of guidance and the end of SUSTOL sales further reduce forward visibility.

Analysis

The announcement is factual and restrained, with no evidence of exaggerated or promotional language. All key claims are supported by realised, historical financial data, including detailed revenue, gross profit, operating expenses, and net loss figures. The only forward-looking element is the pending asset sale to CorMedix, which is clearly described as subject to stockholder approval and closing conditions, not presented as a certainty. The withdrawal of financial guidance and cessation of SUSTOL sales are disclosed plainly, without positive spin. The financial direction is negative, with declining revenue and ongoing losses, and the company is not attempting to inflate its narrative or obscure these facts. There is no large capital outlay or long-dated benefit projection in this release.

Risk flags

• ●Heron is operating at a loss, with a Q3 2026 net loss of $5.0 million and a nine-month net loss of $18.6 million, indicating ongoing negative cash flow and raising questions about liquidity and sustainability.
• ●Total net revenue is declining, falling 7.8% year-over-year in Q3 and sequentially from Q2, suggesting deteriorating top-line performance and limited organic growth.
• ●The company has ceased commercial sales of SUSTOL as of September 30, 2026, eliminating a revenue stream and increasing dependence on a shrinking product portfolio.
• ●The asset sale to CorMedix is not yet closed and is contingent on shareholder approval and other unspecified closing conditions, introducing execution risk and uncertainty about the company's future structure and financial position.
• ●Withdrawal of full-year 2026 guidance in August and absence of new guidance signal management's limited visibility into future performance and heighten uncertainty for investors.

Bottom line

Heron Therapeutics is reporting shrinking revenue, persistent operating and net losses, and a cash position of $23.4 million as of September 30, 2026. The company's Acute Care products are growing, but this is outweighed by steep declines in Oncology revenue and the complete cessation of SUSTOL sales. The planned sale of nearly all assets to CorMedix offers a potential path forward but is not yet finalized and carries significant execution risk. With no financial guidance and ongoing losses, the outlook remains highly uncertain until the asset sale closes and the company clarifies its future direction. The most important takeaway is that Heron's current business is unsustainable without a successful asset sale or a dramatic turnaround.

Announcement summary

(NASDAQ:HRTX) Heron Therapeutics, Inc. announced financial results for the three and nine months ended September 30, 2026, and provided recent corporate updates. Total net revenue for Q3 2026 was $35.3 million, compared to $38.2 million in Q3 2025 and $37.7 million in Q2 2026. The company ended the third quarter with $23.4 million in cash, cash equivalents, and short-term investments. Acute Care franchise net revenue increased 22.5% year-over-year for Q3 2026 and 32.4% year-over-year for the nine months ended September 30, 2026. ZYNRELEF contributed $10.6 million and $31.9 million in net revenue for the three and nine months ended September 30, 2026, respectively. APONVIE contributed $4.5 million and $12.2 million in net revenue for the three and nine months ended September 30, 2026, respectively. Oncology Supportive Care franchise net revenue was $20.1 million in Q3 2026 and $63.5 million for the nine months ended September 30, 2026. CINVANTI contributed $20.0 million and $62.3 million in net revenue for the three and nine months ended September 30, 2026, respectively. Commercial sales of SUSTOL ceased on September 30, 2026. Heron and CorMedix Therapeutics entered into a definitive asset purchase agreement for CorMedix to acquire substantially all of Heron's assets, subject to Heron stockholder approval and customary closing conditions. The company withdrew its full-year 2026 financial guidance in August 2026 and is not providing guidance at this time. For Q3 2026, Acute Care net revenue was $15,128,000, APONVIE $4,530,000, ZYNRELEF $10,598,000, Oncology $20,122,000, CINVANTI $19,970,000, SUSTOL $152,000, and total net revenue $35,250,000. For the nine months ended September 30, 2026, Acute Care net revenue was $44,088,000, APONVIE $12,200,000, ZYNRELEF $31,888,000, Oncology $63,539,000, CINVANTI $62,298,000, SUSTOL $1,241,000, and total net revenue $107,627,000. Cost of product sales for Q3 2026 was $8,958,000 and for the nine months ended September 30, 2026 was $31,168,000. Gross profit for Q3 2026 was $26,292,000 and for the nine months ended September 30, 2026 was $76,459,000. Operating expenses for Q3 2026 were $27,961,000 and for the nine months ended September 30, 2026 were $84,937,000. Loss from operations was $1,669,000 for Q3 2026 and $8,478,000 for the nine months ended September 30, 2026. Net loss was $5,006,000 for Q3 2026 and $18,606,000 for the nine months ended September 30, 2026. Comprehensive loss was $5,007,000 for Q3 2026 and $18,617,000 for the nine months ended September 30, 2026. Basic net loss per share was $0.03 for Q3 2026 and $0.10 for the nine months ended September 30, 2026. Heron will not host a conference call or webcast for its third quarter 2026 financial results.

Disagree with this article?